Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib plus hydroxychloroquine versus hydroxychloroquine for early COVID-19 interstitial pneumonia
2020-002035-30Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and viral pneumonia comparing Tofacitinib plus hydroxychloroquine with Hydroxychloroquine (2 arms). Primary endpoint: Need for mechanical ventilation. Started Jun 2020; status: completed.
02
Drugs
tofacitinibhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-002035-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002035-30.